Bhutan vs Sri Lanka: Average cost of multi drug-resistant tuberculosis treatment
Bhutan
886 constant 2022 US$
in 2024
Sri Lanka
902 constant 2022 US$
in 2024
Bhutan rank
55th
Sri Lanka rank
52nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Bhutan
- Sri Lanka
How they compare
Sri Lanka currently reports 902 constant 2022 US$ against 886 constant 2022 US$ in Bhutan, a difference of 16 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Sri Lanka ahead.
Bhutan ranks 55th and Sri Lanka ranks 52nd of 92 countries.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bhutan | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,204 constant 2022 US$ | 2,695 constant 2022 US$ | 1,491 constant 2022 US$ | Sri Lanka |
| 2020s | 864.4 constant 2022 US$ | 1,439 constant 2022 US$ | 575 constant 2022 US$ | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bhutan or Sri Lanka?
- Sri Lanka, at 902 constant 2022 US$ against 886 constant 2022 US$ in Bhutan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bhutan and Sri Lanka?
- 16 constant 2022 US$, with Sri Lanka ahead.
- How many years of comparable data are there for Bhutan and Sri Lanka?
- 8 years are reported by both, from 2017 to 2024.
- How do Bhutan and Sri Lanka rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bhutan ranks 55th and Sri Lanka ranks 52nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.